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difference being that the primary site of oligometastases was 
uncontrolled (sync-oligometastases) or controlled (oligo-
recurrence). The goal of this multicenter study was to 
evaluate treatment outcomes and to evaluate factors 
affecting relapse-free survival (RFS) after stereotactic body 
radiotherapy (SBRT) for pulmonary oligometastases. 
Materials and Methods: A total of 96 patients (65 males and 
31 females) who received SBRT for oligometastatic lung 
tumors between January 2004 and April 2014 at 4 high-
volume institutions in Japan were enrolled in this 
retrospective study. The primary sites were the colorectum 
(n=25), lung (n=24), head and neck (n=8), uterus (n=8) and 
others (n=31), and the pathologies of primary cancers were 
adenocarcinoma (n=49), squamous cell caricinoma (n=19), 
others (n=12) and pathologically unproven (n=16). The 
median tumor diameter was 19 mm (range, 6-42 mm). Ten 
cases were sync-oligometastases and 79 cases were oligo-
recurrences. The median disease-free interval (DFI) between 
initial therapy and SBRT was 24 months (range, 0-246 
months). The median calculated biological effective dose was 
105.6 Gy (range, 75-134.4 Gy) using the LQ model with 
alpha/beta = 10 Gy. The prescribed dose was delivered to the 
isocenter (n=56) or covering 95% of the PTV (D95, n=40). 
Cumulative overall survival (OS), local control rate (LCR) and 
RFS rate were calculated using Kaplan-Meier curves, and the 
log-rank test was used to compare the curves. Multivariate 
analysis for RFS was performed using a Cox proportional 
hazards model. Statistical significance was defined as a value 
of p < 0.05 in this study. 
Results: The median follow-up periods were 21 months 
(range, 1-119 months) for all patients and 32 months (range, 
1-119 months) for survivors. The 3-year OS, LCR and RFS rates 
were 52%, 75% and 25%, respectively. Radiation pneumonitis 
of grade 3 was found in 2 patients and gastrointestinal 
toxicity of grade 4 was found in 1 patient. No grade 5 toxicity 
occurred. The 3-year RFS for sync-oligometastases was 0% 
and that for oligo-recurrence was 28% (Figure, p < 0.01). The 
3-year RFS for the subgroup of DFI < or = 24 months and that 
for the subgroup of DFI > 24 months were 17% and 34%, 
respctively (p = 0.01). In multivariate analysis, sync-
oligometastases (p = 0.01), multiple oligometastatic tumors 
(p = 0.01) and D95 (p = 0.02) were significantly unfavorable 
factors for RFS. 
 
 
 
Conclusions: In SBRT for oligometastatic lung tumors, control 
of the primary site is a significant prognostic factor for RFS. 
Single oligo-recurrence tumor in the lung could be a good 
candidate for SBRT.  
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Purpose/Objective: In the multicenter PET-Plan study, which 
is comparing FDG–PET based treatment planning for 
chemoradiotherapy of NSCLC with conventional target 
volumes in terms of loco-regional progression the cardiac 
dose is an important planning criterion. The presented study 
examines the extent of deviation of delineated heart 
contours from two study centers compared to the per- 
rotocol delineation and its effect on the heart dose with 
particular consideration of the dose distribution. 
Materials and Methods: Heart contours from 59 patients of 
two study centers were re-delineated in strict adherence to 
the study protocol (starting just below the level in which the 
pulmonary trunk branches into the left and right PA, ending 
where the heart blends with the diaphragm). The volumes 
and dose values of the original contours of both centers were 
compared with the values resulting from the protocol-
compliant delineation with Student's t - test. 
Results: The original heart contours of the centers were too 
small in every case compared to the respected protocol 
specification [684,10 ± 302,37 cm3 versus 868,18 ± 219,97 
cm3]. The difference was highly significant with 
p=1.267*10-14. The heart dose-volume parameters of the 
original study center contours were compared with the 
results from the protocol-oriented delineation values, 
significantly smaller (Dmax: p=0,00068; V5:  p=0,00013; 
V40: p=3,4*10-9). In three cases, the study protocol’s 
restriction (V40 ≤ 50 %) was exceeded after correct 
delineation of the heart with a percentage of 54,55%, 60,12% 
respectively 58,04%. 
Conclusions: Incorrect delineation of the heart can lead to a 
misinterpretation of the actual organ dose. In individual 
cases this can be associated with the presumption that 
specific dose restrictions are met, even though dose limits 
are already exceeded. 
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Purpose/Objective: To evaluate the feasibility and efficacy 
of simultaneous integrated boost intensity-modulated 
radiation therapy (SIB-IMRT) in patients with limited-disease 
small cell lung cancer (LD-SCLC). 
Materials and Methods: Patients with LD-SCLC were treated 
with SIB-IMRT within 1 week after completion of 2 cycles of 
induction chemotherapy. Then 2-4 cycles of adjuvant 
chemotherapy were administered within 1 week after SIB-
IMRT. Irradiation was given accelerated hyper-fractionated 
with the prescribed dose 57 Gy at 1.9 Gy twice daily to the 
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gross tumor volume , 51 Gy at 1.7 Gy twice daily to the 
clinical tumor volume and 45 Gy at 1.5 Gy twice daily to the 
planning target volume . The chemotherapy regimen 
consisted of platinum plus etoposide. Prophylactic cranial 
radiation (25 Gy in 10 fractions) was administered to patients 
who got complete response (CR) or near complete response 
(nCR). The primary endpoint of this study was the frequency 
of grade 3 or higher acute non-hematologic treatment-
related toxicities. Secondary end points included objective 
response, overall survival (OS), progression-free survival 
(PFS), locoregional recurrence-free survival (LRFS). 
Results: A cohort of 35 patient enrolled in the study,the 
biological equivalent dose (BED) of the GTV in the SIB-IMRT 
was 59.16 Gy. Grade 1, 2, and 3 esophagitis was observed in 
11 (31%), 12 (34%), and 6 (17%) patient, respectively; Grade 1 
and 2 pneumonitis was observed in 8 (23%) and 4 (11%) 
patient, respectively. The median OS and PFS of the whole 
group was 37.7 months and 29.3 months, respectively. The 1- 
and 2-year OS was 94.1% and 68.5%, respectively. The 1- and 
2-year PFS was 76.8% and 40.7%, respectively. The 1- and 2-
year LRFS was 87.7% and 73.8%, respectively. 
Conclusions: SIB-IMRT was safe and effective in patients with 
LD-SCLC, and worth further evaluating in a large prospective 
clinical trial.  
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Purpose/Objective: Concurrent chemoradiotherapy (CCRT) is 
the standard treatment for locally advanced stage III non-
small-cell lung cancer (NSCLC) in patients with a good 
performance and minimal weight loss. The aim of this study 
was to define subgroups with different survival and to 
identify the correlation to the radiation-related toxicities. 
Materials and Methods: We retrospectively reviewed 381 
locally advanced stage III NSCLC patients with CCRT between 
2004 and 2011. Three-dimensional conformal radiotherapy 
was given once daily and combined with weekly 
chemotherapy. We evaluated the age, gender, stage, initial 
white blood cell count, hemoglobin level, forced expiratory 
volume in 1 second (FEV1), diffusion lung capacity for carbon 
monoxide (DLCO), gross tumor volume (GTV), extent of nodal 
involvement as the prognostic factors. 
Results: By multivariate Cox modeling, age (>75 years, p = 
0.011), DLCO (≤80%, p = 0.011), GTV (≥100 cm3, p3 had more 
severe ≥ grade 3 radiation esophagitis. The interruption rate 
of radiotherapy was significantly different between the 
prognostic subgroups; group I, II, III and IV had incidences of 
8.8%,15.4%, 22.7%, and 30.6%, respectively (p= 0.017). 
Conclusions: The severe treatment toxicity and interruption 
of radiotherapy was more frequently seen in patients with 
multiple adverse prognostic factors. To maintain the survival 
benefit from CCRT, we need the strategies to reduce the 
treatment-related toxicities. The controversial issue on the 
impact of subcarinal lymph node involvement seems to be 
worthy of investigation in subsequent prospective, 
randomized trials.  
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Purpose/Objective: RTOG 0617 has demonstrated that the 
percentage of heart receiving between 5 and 30 Gy is 
correlated with survival.This study investigated the accuracy 
of cardiac outlining carried out by individual clinicians and 
the subsequent effect on recorded cardiac dose. 
Materials and Methods: The CONVERT Trial is a multicentre 
phase III study which recruited 547 patients with limited-
stage SCLC. Patients were randomised to receive once daily 
(66Gy in 33 fractions) or twice daily (45Gy in 30 fractions) 
radiotherapy concurrently with chemotherapy.  
The trial protocol specified that the heart and pericardial sac 
should be contoured. Outlining extended superiorly to the 
inferior aspect of the aortic arch and inferiorly to the apex of 
the heart. An atlas was provided which included heart 
contours.  
Each clinician completed a planning exercise which assessed 
patient selection, disease and organs at risk outlining, margin 
expansion and treatment plan. Centres were asked to 
anonymise and transfer data to the Mount Vernon Quality 
Assurance (QA) team which was reviewed using VODCA 
(Visualisation and Organisation of Data for Cancer Analysis), 
version 3.2.7. In this study, heart outline volumes provided 
by participating centres were compared to the gold standard 
heart volumes (in cm3) drawn according to the trial protocol 
for 28 patients. 
Results: one of the 28 cases delineated the heart according 
to protocol. The most common outlining discrepancy was that 
the cardiac outline was not countoured superiorly enough to 
the inferior aspect of the aortic arch (96.4% of cases). The 
average difference in volume between that provided by the 
centre and the gold standard was 85.1cm3 (range 5.6cm3 to 
248.2cm3).  
In 100% of cases the heart was not outlined according to 
protocol and in 89.3% of cases the cardiac dose was 
underestimated (by 29.1%) as a result of deviation of the 
heart outline from the protocol. An increase in calculated 
cardiac dose was reported in 85.7% of cases in the 
experimental dose arm (range 0.98%-90.5%) and in 92.9% of 
cases in the control arm (range 0.6%-90.4%).  
Conclusions: In this study we have shown that in every case 
reviewed the heart was not delineated according to protocol. 
As a result the mean heart dose was underestimated by an 
average of 29.1%.  
In conclusion, this study highlights the importance of 
collecting radiotherapy plans to check heart coutours as part 
